MRC Transition Support CSF Alexandra Santos
Lead Research Organisation:
King's College London
Department Name: Asthma Allergy and Lung Biology
Abstract
The symptoms of food allergy (FA) result from the release of certain substances by cells of the immune system, called mast cells and basophils, triggered by the interaction between allergy antibodies (called IgE) and food allergens. FA is often diagnosed using skin prick test or by detecting IgE (allergy antibodies) in the blood. However, more common than being food allergic is to have a positive allergy test to that food. For example, only 1 out of 5 children with a positive allergy test to peanut in the United Kingdom has peanut allergy. In the equivocal cases (more than 50% of patients), an oral food challenge (OFC) is required. OFC consists in giving the patient the suspected food in a controlled environment to see whether the patient develops an allergic reaction. OFC are quite expensive, time-consuming and place the patient at risk of a potentially severe reaction, but this is currently the gold-standard for the diagnosis of FA.
Funded by the MRC, I developed a new blood test called the basophil activation test (BAT) that works like an OFC in a test tube in the sense that allergen is added to cells in blood rather than food to the potentially allergic child, sparing patients from experiencing an allergic reaction. BAT to peanut showed 97% accuracy in the diagnosis of peanut allergy and reduced the need for OFC by two thirds. More recently, I have developed the BAT to cow's milk, egg, sesame and cashew nut and we are now assessing how useful BAT is to diagnose milk and egg allergies, which are the most common food allergies in childhood, and cashew and sesame allergies, which are two of the foods that most commonly require OFC as conventional allergy tests fail to diagnose allergy correctly. For this, we are inviting children with suspected food allergies to participate into the BAT 2 study, which is currently underway. Because BAT requires the use of fresh blood cells thus I developed a test similar to BAT using cells that are grown in the laboratory and thus are readily available - this is called the mast cell activation test (MAT). We have tested various samples of peanut allergic and non-allergic patients and showed that MAT confirms peanut allergy with a high degree of certainty. I anticipate that BAT and MAT will lead to a significant improvement of care for allergic patients and will reduce the costs and anxiety associated with OFC. Due to reasons beyond my control, there were some delays in the start and in recruiting to the BAT2 Study and the Transition Support would allow me to complete the study and obtain evidence to support advancing the development of these tests for clinical use.
To understand why some patients have a positive allergy test and are not allergic, we have been studying the antibodies of allergic and non-allergic children. We have shown that the IgE of allergic patients has different characteristics from the IgE of non-allergic subjects and that non-allergic subjects who have the allergy antibodies tend to have blocking antibodies to counteract the IgE. We would now like to understand why the immune system of allergic and non-allergic subjects responds differently to food allergens in the first place, and will be testing samples that have been collected from participants in the BAT 2 study. By comparing the responses of T cells (which are the coordinators of the immune system) between allergic and non-allergic patients and between allergens that are known to cause life-long allergies with allergens that cause allergies that typically resolve, we will improve our understanding of why some children are allergic and others not, may find ways to turn off the allergic response and identify new targets for a curative treatment for FA. The MRC Transition Support would enable be to gather experimental data to support a future Senior Fellowship Application to explore these mechanisms in the future.
Funded by the MRC, I developed a new blood test called the basophil activation test (BAT) that works like an OFC in a test tube in the sense that allergen is added to cells in blood rather than food to the potentially allergic child, sparing patients from experiencing an allergic reaction. BAT to peanut showed 97% accuracy in the diagnosis of peanut allergy and reduced the need for OFC by two thirds. More recently, I have developed the BAT to cow's milk, egg, sesame and cashew nut and we are now assessing how useful BAT is to diagnose milk and egg allergies, which are the most common food allergies in childhood, and cashew and sesame allergies, which are two of the foods that most commonly require OFC as conventional allergy tests fail to diagnose allergy correctly. For this, we are inviting children with suspected food allergies to participate into the BAT 2 study, which is currently underway. Because BAT requires the use of fresh blood cells thus I developed a test similar to BAT using cells that are grown in the laboratory and thus are readily available - this is called the mast cell activation test (MAT). We have tested various samples of peanut allergic and non-allergic patients and showed that MAT confirms peanut allergy with a high degree of certainty. I anticipate that BAT and MAT will lead to a significant improvement of care for allergic patients and will reduce the costs and anxiety associated with OFC. Due to reasons beyond my control, there were some delays in the start and in recruiting to the BAT2 Study and the Transition Support would allow me to complete the study and obtain evidence to support advancing the development of these tests for clinical use.
To understand why some patients have a positive allergy test and are not allergic, we have been studying the antibodies of allergic and non-allergic children. We have shown that the IgE of allergic patients has different characteristics from the IgE of non-allergic subjects and that non-allergic subjects who have the allergy antibodies tend to have blocking antibodies to counteract the IgE. We would now like to understand why the immune system of allergic and non-allergic subjects responds differently to food allergens in the first place, and will be testing samples that have been collected from participants in the BAT 2 study. By comparing the responses of T cells (which are the coordinators of the immune system) between allergic and non-allergic patients and between allergens that are known to cause life-long allergies with allergens that cause allergies that typically resolve, we will improve our understanding of why some children are allergic and others not, may find ways to turn off the allergic response and identify new targets for a curative treatment for FA. The MRC Transition Support would enable be to gather experimental data to support a future Senior Fellowship Application to explore these mechanisms in the future.
Technical Summary
The majority of children with food-specific IgE do not have food allergy (FA). In equivocal cases, oral food challenges (OFC) are required. However, these are expensive, time-consuming and can cause allergic reactions.
Aims:
1. To improve the diagnosis of food allergy using the basophil activation test (BAT) and the mast cell activation test (MAT);
2. To understand the molecular and cellular basis underpinning FA and tolerance in IgE-sensitised children.
Methodology:
Following the success of BAT to peanut in diagnosing food allergy (97% accuracy and 66% reduction in OFC), we have developed the BAT to milk, egg, cashew and sesame and are currently assessing the diagnostic utility of BAT to diagnose allergy to these foods in the BAT2 Study. Children with suspected allergies to these foods have been invited to participate and BAT has been performed in real-time. MAT has been done in parallel as it has the advantage of providing results for subjects with non-responding basophils and of using stored rather than fresh blood samples, which allows to test samples collected far from the lab or in the past. The performance of BAT and MAT will be compared with the gold-standard OFC.
In order to better understand why some children with food-specific IgE react to the food whereas others do not and also why some FA resolve whereas others tend to be persistent, we will be studying how different subsets of T cells respond to allergen in allergic versus non-allergic patients and in transient versus persistent food allergies. These experiments will provide the foundation for a future Senior Fellowship application.
Scientific and medical opportunities:
With the validation of the BAT and the MAT to diagnose common food allergies, we will improve the accuracy and the safety of food allergy diagnosis. By comparing the T cell response between patients and between allergens, we will identify potential targets for a definitive treatment of FA, which we currently do not have.
Aims:
1. To improve the diagnosis of food allergy using the basophil activation test (BAT) and the mast cell activation test (MAT);
2. To understand the molecular and cellular basis underpinning FA and tolerance in IgE-sensitised children.
Methodology:
Following the success of BAT to peanut in diagnosing food allergy (97% accuracy and 66% reduction in OFC), we have developed the BAT to milk, egg, cashew and sesame and are currently assessing the diagnostic utility of BAT to diagnose allergy to these foods in the BAT2 Study. Children with suspected allergies to these foods have been invited to participate and BAT has been performed in real-time. MAT has been done in parallel as it has the advantage of providing results for subjects with non-responding basophils and of using stored rather than fresh blood samples, which allows to test samples collected far from the lab or in the past. The performance of BAT and MAT will be compared with the gold-standard OFC.
In order to better understand why some children with food-specific IgE react to the food whereas others do not and also why some FA resolve whereas others tend to be persistent, we will be studying how different subsets of T cells respond to allergen in allergic versus non-allergic patients and in transient versus persistent food allergies. These experiments will provide the foundation for a future Senior Fellowship application.
Scientific and medical opportunities:
With the validation of the BAT and the MAT to diagnose common food allergies, we will improve the accuracy and the safety of food allergy diagnosis. By comparing the T cell response between patients and between allergens, we will identify potential targets for a definitive treatment of FA, which we currently do not have.
Planned Impact
The proposed research aims to improve the diagnosis of food allergy (FA) by using a very accurate newly developed blood test, to validate novel biomarkers of food allergy and tolerance and to improve our understanding of the mechanism that mediate food allergy and tolerance. The ultimate goals of this project are to create an accurate safe noninvasive diagnostic test for food allergy eliminating the need for oral food challenge (OFC) and to identify key targets for future interventions to treat and prevent allergic disease.
FA affects 8% of children and 2% of adults in Western countries. FA has become a significant public health concern; an increased prevalence resulted in an increased incidence in anaphylaxis, which can be fatal. There is no curative treatment for FA and the mainstay of management remains allergen avoidance and the use of rescue treatment for accidental reactions. FA affects the quality of life of allergic children and their families due to dietary and social restrictions and to anxiety related to the life-threatening nature of FA.
The majority of patients with a positive allergy test are not allergic. In equivocal cases, which constitute about 50% of patients seen in an Allergy clinic, OFC are required to diagnose FA. However, OFC are laborious and expensive procedures that place the patient at risk of a potentially severe allergic reaction. In my previous research, the basophil activation test (BAT) proved to be very accurate (97%), with 98% sensitivity and 96% specificity, and was superior to other diagnostic tests in discriminating between peanut allergy and tolerance. BAT reduced the need for oral food challenges by two thirds. I now propose to expand the use of BAT to the diagnosis of other food allergies.
The key beneficiaries from this research include:
1. The immediate and wider science communities
(see Academic Beneficiaries)
2. The health care system and society
I anticipate that the validation of more accurate diagnostic tests (BAT and MAT) for various foods allergies will substantially improve the care for patients with suspected FA, not only by improving the diagnostic accuracy but mainly by reducing the number of OFC required. The reduction in the number of OFC will have direct and indirect economic implications for the health care system: the costs of BAT are lower than those of OFC, BAT is less time-consuming and does not require a multidisciplinary highly-trained clinical team and eliminates the anxiety and risk associated with OFC. This will improve the safety and comfort of FA diagnosis.
3. The food industry
Determination of thresholds is useful for the Public Health Authorities and for the Food Industry to establish regulatory measures to protect food allergic patients and to institute allergen control measures and labelling policies. However, this requires the performance of graded OFC in patients known to be allergic. In my previous work, BAT informed about threshold of allergic reactions to peanut. The same could be determined for other foods.
4. Patient organisations and patients
(see Pathways to Impact)
5. Key established and new industry partners who can develop new paradigms for drug testing based on our mechanistic findings
My work will also open new potential research areas for exploitation. The discovery of new mechanisms underlying FA and tolerance will have significant potential to build on existing collaborations with industry and develop new industry collaborations. The same applies to the standardisation of BAT as a diagnostic tool in FA and making this test commercially available to multiple foods. All these possibilities will be of interest to industry especially for testing new therapies based on the immunological discovery of new targets. Furthermore, the close collaboration between clinicians and scientists fostered by my project will benefit both parties and create stronger links for further collaboration and translational activity.
FA affects 8% of children and 2% of adults in Western countries. FA has become a significant public health concern; an increased prevalence resulted in an increased incidence in anaphylaxis, which can be fatal. There is no curative treatment for FA and the mainstay of management remains allergen avoidance and the use of rescue treatment for accidental reactions. FA affects the quality of life of allergic children and their families due to dietary and social restrictions and to anxiety related to the life-threatening nature of FA.
The majority of patients with a positive allergy test are not allergic. In equivocal cases, which constitute about 50% of patients seen in an Allergy clinic, OFC are required to diagnose FA. However, OFC are laborious and expensive procedures that place the patient at risk of a potentially severe allergic reaction. In my previous research, the basophil activation test (BAT) proved to be very accurate (97%), with 98% sensitivity and 96% specificity, and was superior to other diagnostic tests in discriminating between peanut allergy and tolerance. BAT reduced the need for oral food challenges by two thirds. I now propose to expand the use of BAT to the diagnosis of other food allergies.
The key beneficiaries from this research include:
1. The immediate and wider science communities
(see Academic Beneficiaries)
2. The health care system and society
I anticipate that the validation of more accurate diagnostic tests (BAT and MAT) for various foods allergies will substantially improve the care for patients with suspected FA, not only by improving the diagnostic accuracy but mainly by reducing the number of OFC required. The reduction in the number of OFC will have direct and indirect economic implications for the health care system: the costs of BAT are lower than those of OFC, BAT is less time-consuming and does not require a multidisciplinary highly-trained clinical team and eliminates the anxiety and risk associated with OFC. This will improve the safety and comfort of FA diagnosis.
3. The food industry
Determination of thresholds is useful for the Public Health Authorities and for the Food Industry to establish regulatory measures to protect food allergic patients and to institute allergen control measures and labelling policies. However, this requires the performance of graded OFC in patients known to be allergic. In my previous work, BAT informed about threshold of allergic reactions to peanut. The same could be determined for other foods.
4. Patient organisations and patients
(see Pathways to Impact)
5. Key established and new industry partners who can develop new paradigms for drug testing based on our mechanistic findings
My work will also open new potential research areas for exploitation. The discovery of new mechanisms underlying FA and tolerance will have significant potential to build on existing collaborations with industry and develop new industry collaborations. The same applies to the standardisation of BAT as a diagnostic tool in FA and making this test commercially available to multiple foods. All these possibilities will be of interest to industry especially for testing new therapies based on the immunological discovery of new targets. Furthermore, the close collaboration between clinicians and scientists fostered by my project will benefit both parties and create stronger links for further collaboration and translational activity.
Organisations
- King's College London (Lead Research Organisation)
- Charité - University of Medicine Berlin (Collaboration)
- King's College Hospital (Collaboration)
- University of Chicago (Collaboration)
- National Jewish Medical and Research Center, USA (Collaboration)
- Federal University of São Paulo (Collaboration)
- Southampton Hospital (Collaboration)
- UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST (Collaboration)
- Benaroya Research Institute (Collaboration)
- Royal Manchester Children's Hospital (Collaboration)
- SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST (Collaboration)
- UNIVERSITY OF EDINBURGH (Collaboration)
- University College Hospital (Collaboration)
- Murdoch Children's Research Institute (Collaboration)
- NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- Stanford University (Collaboration)
- Sheffield Children's Hospital (Collaboration)
- Immune Tolerance Network (Collaboration)
- Addenbrooke's Hospital (Collaboration)
- Curie Institute Paris (Institut Curie) (Collaboration)
- University of Bonn (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
Publications

Anagnostou A
(2023)
The future of food allergy: Challenging existing paradigms of clinical practice.
in Allergy

Anagnostou K
(2023)
The Future of Food Allergy: Challenging Existing Paradigms of Clinical Practice.

Barber D
(2021)
Molecular allergology and its impact in specific allergy diagnosis and therapy.
in Allergy

Bartha I
(2024)
Feast for thought: A comprehensive review of food allergy 2021-2023.
in The Journal of allergy and clinical immunology

Bergmann M
(2024)
Basophil activation test in the food allergy clinic: its current use and future applications
in Expert Review of Clinical Immunology

Brough H
(2021)
Early intervention and prevention of allergic diseases
in Allergy

Conway AE
(2024)
Serologic measurements for peanut allergy: Predicting clinical severity is complex.
in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

Croote D
(2024)
Preclinical efficacy of peanut-specific IgG4 antibody therapeutic IGNX001
in Journal of Allergy and Clinical Immunology

Dramburg S
(2023)
EAACI Molecular Allergology User's Guide 2.0.
in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology

Eigenmann P
(2023)
Editorial comments on: "Immune-related microRNAs in breast milk and their relation to regulatory T cells in breastfed children".
in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
Description | Chair of the Research and Outreach Committee Food Allergy Group of the European Academy of Allergy and Clinical Immunology |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | EAACI Food Allergy Guidelines (Chair) |
Geographic Reach | Europe |
Policy Influence Type | Participation in a guidance/advisory committee |
URL | https://eaaci.org/news/new-clinical-guidelines-for-the-diagnosis-of-immediate-type-food-allergies-ar... |
Guideline Title | EAACI Food Allergy Guidelines |
Description | The basophil activation test is for the first time recommended as a test for food allergy |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Citation in clinical guidelines |
Description | WHO IUIS Allergen Nomenclature Committee Member |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Membership of a guideline committee |
Description | ERA-HDHL Call for Joint Transnational Research Proposals: "Addressing adverse and beneficial effects of food ingredients and food processing on hypersensitivities to food" (FOOD_HYPERSENS) |
Amount | £1,000,000 (GBP) |
Funding ID | BB/X002519/1 |
Organisation | King's College London |
Sector | Academic/University |
Country | United Kingdom |
Start | 03/2022 |
End | 03/2025 |
Description | Food Allergy Research and Education |
Amount | $500,000 (USD) |
Organisation | Food Allergy Research and Education (FARE) |
Sector | Charity/Non Profit |
Country | United States |
Start | 03/2021 |
End | 04/2024 |
Description | MRC Transition Support CSF Alexandra Santos |
Amount | £700,773 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 07/2020 |
End | 07/2022 |
Description | MRC-DTP PhD Programme |
Amount | £82,227 (GBP) |
Organisation | King's College London |
Sector | Academic/University |
Country | United Kingdom |
Start | 08/2021 |
End | 08/2024 |
Description | Mast cell activation in the EAT and EAT-On Study |
Amount | £10,000 (GBP) |
Organisation | National Institute for Health Research |
Sector | Public |
Country | United Kingdom |
Start | 01/2021 |
End | 03/2022 |
Description | National Institutes of Health (NIH) |
Amount | £40,985 (GBP) |
Organisation | National Institutes of Health (NIH) |
Sector | Public |
Country | United States |
Start | 03/2021 |
End | 12/2021 |
Description | Understanding how environmental cutaneous exposure to peanut protein might cause food allergy in early life |
Amount | £95,000 (GBP) |
Organisation | Rosetrees Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 03/2023 |
End | 01/2026 |
Description | Wellcome Trust PhD Programme on Neuroimmunology |
Amount | £205,252 (GBP) |
Organisation | King's College London |
Sector | Academic/University |
Country | United Kingdom |
Start | 09/2021 |
End | 09/2025 |
Title | Predicting Allergic Reactions During Oral Peanut Challenges |
Description | his prediction tool calculates the reaction severity based on a published model developed from the LEAP, LEAP-On, and PAS studies. This tool uses the basophil activation test (BAT), skin prick test (SPT) size (mm), and the level of Ara h 2-specific IgE (kU/L) to predict reaction severity defined as no reaction, moderate reaction, or a severe reaction. The values of these biomarkers are combined to give the predicted probabilities of falling into each of the severity categories. This tool may be useful for clinicians when assessing the risk of conducting oral food challenges to diagnose peanut allergy. All study details and modeling are outlined in "Santos AF, et al., Biomarkers of severity and threshold of allergic reactions during oral peanut challenges. J Allergy Clin Immunol. 2020 Aug;146(2):344-355. PMID: 32311390." |
Type Of Material | Computer model/algorithm |
Year Produced | 2021 |
Provided To Others? | Yes |
Impact | This tool has been useful for clinical teams to determine the likelihood of patients to react during peanut challenges. |
URL | https://benaroyaresearch.shinyapps.io/peanutallergytool/ |
Description | Basophil activation test in the TREAT study |
Organisation | Murdoch Children's Research Institute |
Country | Australia |
Sector | Academic/University |
PI Contribution | I have provided my expert advise and intellectual input in the design of experiments to assess basophil activation to tree nuts in children recruited into the Treeat Trial. |
Collaborator Contribution | Treeat is an interventional randomised controlled study to find out if the introduction of multiple tree nuts in a hospital oral food challenge is better for prevention of tree nut allergy and is easier for families, than standard care. |
Impact | None |
Start Year | 2021 |
Description | Basophil activation test to diagnose cow's milk allergy in Brazil |
Organisation | Federal University of São Paulo |
Country | Brazil |
Sector | Academic/University |
PI Contribution | I have provided expert advice on the study design and experimental set up of a study on the utility of the basophil activation test to diagnose cow's milk allergy in Sao Paulo. I have trained the PI of the study on the basophil activation test in my lab during a Sabbatical visit in 2020. |
Collaborator Contribution | My collaborator is setting up and leading the study in Brazil. |
Impact | Not yet. |
Start Year | 2020 |
Description | Immune-gut interactions in food allergy and oral tolerance |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | This is an MRC-funded PhD studentship, part of the MRC-DTP Programme at KCL, where I am PhD Supervisor, co-supervising the student with Dr Joana Neves from KCL. Me and my team contribute at least 50% of the resources needed for the project, including expertise, intellectual input, training of PhD student and access to data, equipment and lab facilities. |
Collaborator Contribution | Dr Joana Neves and I co-supervise the student and the Neves Lab contributes with the other 50% of the resources needed for the project. |
Impact | This collaboration is multidisciplinary as it involves Allergy, Immunology, stem cell biology and gut organoid platform. The direct output from this collaboration was a conference abstract presented at the Immunology Winter School of the European Academy of Allergy and Clinical Immunology. |
Start Year | 2021 |
Description | Investigating the impact of food allergic reactions on children's mental health and the underlying neurobiological mechanisms |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | This is a PhD studentship funded by the Wellcome Trust via the Wellcome Trust PhD Programme on Neuroimmunology. I am PhD Supervisor together with Prof Sandrine Thuret. In this model the co-supervision each supervisor and the respective team contribute equally to the project, thus this would be 50%, and includes expertise, intellectual input and training of PhD student, as well as access to data, equipment and lab facilities. Specifically, the student spends 50% of their time in my lab and in the clinical trials unit, recruiting and assessing patients, whose blood samples the student is testing in my lab on the mast cell activation test to cow's milk and other food allergens. The student will use the mast cell line to explore the immune mechanisms of the interaction between the allergic mediators of mast cells and the neurons from the hippocampus which could explain the modifications of neurogenesis underlying anxiety and changes in mood and cognition induced by allergic reactions and anaphylaxis. |
Collaborator Contribution | Prof Thuret and the Thuret Lab contribute with 50% of the resources required for the project. The student will spend time in the Thuret Lab testing samples from allergic and non-allergic children in the hippocampal neurogenesis assay and exploring the biologic mechanisms underlying anxiety and changes in mood and cognition induced by allergic reactions to food and anaphylaxis. |
Impact | This collaboration is interdisciplinary and involves Allergy and Immunology and Neuroscience and Psychology. |
Start Year | 2020 |
Description | Modification of antibody function with early peanut consumption |
Organisation | Immune Tolerance Network |
Country | United States |
Sector | Charity/Non Profit |
PI Contribution | My research team will be testing samples of participants in the LEAP, LEAP-On and PAS studies on the mast cell activation test. |
Collaborator Contribution | ITN will be sending plasma samples from participants in the LEAP, LEAP-On and PAS studies alongside with funding to support the experimental work. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | Preventing peanut allergy through improved understanding of the transcutaneous sensitisation route, novel food processing and skin care adaptations (TRANS-FOODS) |
Organisation | Charité - University of Medicine Berlin |
Department | Paediatric Endocrinology Charité |
Country | Germany |
Sector | Academic/University |
PI Contribution | As part of this consortium, I provide expertise on food allergy and risk factors for sensitisation and allergic reactions and also about peanut allergens, their allergenicity and effect of their modification. In my laboratory at King's College London, my team will test the samples of interstitial fluid retrieved from the skin of adults participating in the clinical study planned as part of WP4 to assess the ability of peanut proteins contained in the interstitial skin fluid to interact with immune cells. Specifically, I plan is to use these samples to stimulate basophils in whole blood collected from peanut allergic donors, alongside the relevant controls, and assess basophil activation by flow cytometry. The basophil activation assay to peanut is well established in my laboratory. I have previously shown that it has 97% accuracy with 98% sensitivity and 96% specificity to diagnose peanut allergy with basophil activation being detectable below 1ng/ml of peanut protein. The basophil activation test is therefore a very sensitive and specific method to detect the presence and the allergenicity of peanut proteins. The basophil activation test can be very informative to demonstrate retained allergenicity and immunogenicity of peanut proteins that have crossed the skin barrier in adults, with or without atopic eczema, who have applied different peanut-containing preparations on to the skin. The evidence that sensitisation to food allergens can occur through the skin and the demonstration of the mechanisms by which this happens can potentially identify ways to reduce allergen exposure and to prevent the development of peanut and other food allergies in infants and children and possibly later in the life course. |
Collaborator Contribution | Background: Allergic diseases, including atopic dermatitis (AD) and food allergies (FA), affect over a quarter of all children across Europe. The immune responses to oral food allergens are well-established and controlled oral allergen exposure methods in early life have been developed that can prevent FA. However, it is not easy to comply with the repeated oral allergen exposure required to induce tolerance and additional approaches are therefore needed. There is mounting evidence that early life cutaneous exposure to foods causes sensitisation, especially in the presence of dry skin and AD. Despite this, very little is known about how the cutaneous sensitisation to FA occurs. Aims: This project aims to reduce the risk of peanut allergy development through the transcutaneous route by 1) understanding the mechanisms through which this occurs, and 2) designing and testing novel prevention approaches, such as modification in the peanut manufacturing processes and the adaptation of skin care practices. Workplan: These ambitious, but achievable aims are addressed in integrated workpackages, taken forward by leaders in their respective fields from the UK, Germany, and France: WP1 addresses the effects of food processing upon the solubility of peanut protein and its components in oil and how this relates to the cutaneous exposure to peanut protein. WP2 examines the effect of peanut protein skin contamination and skin appendage trapping. WP3 studies the immune system activation induced by massage and cutaneous peanut exposure. WP4 uses an intervention study approach with skin massage to study the immune responses to peanut allergen in those with a skin barrier defect. WP5 examines the cutaneous immune responses to peanut allergen in those suffering of peanut allergy, and, WP6 translates our findings through working with an industrial peanut processing partner, patients and consumers. Impact of expected results: We will work with the food industry, Allergy UK, the Natasha Allergy Research Foundation, as well as national and international food standards agencies to ensure stakeholder awareness and that the findings of our work are translated into improved public health measures. |
Impact | Not yet |
Start Year | 2021 |
Description | Preventing peanut allergy through improved understanding of the transcutaneous sensitisation route, novel food processing and skin care adaptations (TRANS-FOODS) |
Organisation | Curie Institute Paris (Institut Curie) |
Department | BioPhenics Platform |
Country | France |
Sector | Public |
PI Contribution | As part of this consortium, I provide expertise on food allergy and risk factors for sensitisation and allergic reactions and also about peanut allergens, their allergenicity and effect of their modification. In my laboratory at King's College London, my team will test the samples of interstitial fluid retrieved from the skin of adults participating in the clinical study planned as part of WP4 to assess the ability of peanut proteins contained in the interstitial skin fluid to interact with immune cells. Specifically, I plan is to use these samples to stimulate basophils in whole blood collected from peanut allergic donors, alongside the relevant controls, and assess basophil activation by flow cytometry. The basophil activation assay to peanut is well established in my laboratory. I have previously shown that it has 97% accuracy with 98% sensitivity and 96% specificity to diagnose peanut allergy with basophil activation being detectable below 1ng/ml of peanut protein. The basophil activation test is therefore a very sensitive and specific method to detect the presence and the allergenicity of peanut proteins. The basophil activation test can be very informative to demonstrate retained allergenicity and immunogenicity of peanut proteins that have crossed the skin barrier in adults, with or without atopic eczema, who have applied different peanut-containing preparations on to the skin. The evidence that sensitisation to food allergens can occur through the skin and the demonstration of the mechanisms by which this happens can potentially identify ways to reduce allergen exposure and to prevent the development of peanut and other food allergies in infants and children and possibly later in the life course. |
Collaborator Contribution | Background: Allergic diseases, including atopic dermatitis (AD) and food allergies (FA), affect over a quarter of all children across Europe. The immune responses to oral food allergens are well-established and controlled oral allergen exposure methods in early life have been developed that can prevent FA. However, it is not easy to comply with the repeated oral allergen exposure required to induce tolerance and additional approaches are therefore needed. There is mounting evidence that early life cutaneous exposure to foods causes sensitisation, especially in the presence of dry skin and AD. Despite this, very little is known about how the cutaneous sensitisation to FA occurs. Aims: This project aims to reduce the risk of peanut allergy development through the transcutaneous route by 1) understanding the mechanisms through which this occurs, and 2) designing and testing novel prevention approaches, such as modification in the peanut manufacturing processes and the adaptation of skin care practices. Workplan: These ambitious, but achievable aims are addressed in integrated workpackages, taken forward by leaders in their respective fields from the UK, Germany, and France: WP1 addresses the effects of food processing upon the solubility of peanut protein and its components in oil and how this relates to the cutaneous exposure to peanut protein. WP2 examines the effect of peanut protein skin contamination and skin appendage trapping. WP3 studies the immune system activation induced by massage and cutaneous peanut exposure. WP4 uses an intervention study approach with skin massage to study the immune responses to peanut allergen in those with a skin barrier defect. WP5 examines the cutaneous immune responses to peanut allergen in those suffering of peanut allergy, and, WP6 translates our findings through working with an industrial peanut processing partner, patients and consumers. Impact of expected results: We will work with the food industry, Allergy UK, the Natasha Allergy Research Foundation, as well as national and international food standards agencies to ensure stakeholder awareness and that the findings of our work are translated into improved public health measures. |
Impact | Not yet |
Start Year | 2021 |
Description | Preventing peanut allergy through improved understanding of the transcutaneous sensitisation route, novel food processing and skin care adaptations (TRANS-FOODS) |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | As part of this consortium, I provide expertise on food allergy and risk factors for sensitisation and allergic reactions and also about peanut allergens, their allergenicity and effect of their modification. In my laboratory at King's College London, my team will test the samples of interstitial fluid retrieved from the skin of adults participating in the clinical study planned as part of WP4 to assess the ability of peanut proteins contained in the interstitial skin fluid to interact with immune cells. Specifically, I plan is to use these samples to stimulate basophils in whole blood collected from peanut allergic donors, alongside the relevant controls, and assess basophil activation by flow cytometry. The basophil activation assay to peanut is well established in my laboratory. I have previously shown that it has 97% accuracy with 98% sensitivity and 96% specificity to diagnose peanut allergy with basophil activation being detectable below 1ng/ml of peanut protein. The basophil activation test is therefore a very sensitive and specific method to detect the presence and the allergenicity of peanut proteins. The basophil activation test can be very informative to demonstrate retained allergenicity and immunogenicity of peanut proteins that have crossed the skin barrier in adults, with or without atopic eczema, who have applied different peanut-containing preparations on to the skin. The evidence that sensitisation to food allergens can occur through the skin and the demonstration of the mechanisms by which this happens can potentially identify ways to reduce allergen exposure and to prevent the development of peanut and other food allergies in infants and children and possibly later in the life course. |
Collaborator Contribution | Background: Allergic diseases, including atopic dermatitis (AD) and food allergies (FA), affect over a quarter of all children across Europe. The immune responses to oral food allergens are well-established and controlled oral allergen exposure methods in early life have been developed that can prevent FA. However, it is not easy to comply with the repeated oral allergen exposure required to induce tolerance and additional approaches are therefore needed. There is mounting evidence that early life cutaneous exposure to foods causes sensitisation, especially in the presence of dry skin and AD. Despite this, very little is known about how the cutaneous sensitisation to FA occurs. Aims: This project aims to reduce the risk of peanut allergy development through the transcutaneous route by 1) understanding the mechanisms through which this occurs, and 2) designing and testing novel prevention approaches, such as modification in the peanut manufacturing processes and the adaptation of skin care practices. Workplan: These ambitious, but achievable aims are addressed in integrated workpackages, taken forward by leaders in their respective fields from the UK, Germany, and France: WP1 addresses the effects of food processing upon the solubility of peanut protein and its components in oil and how this relates to the cutaneous exposure to peanut protein. WP2 examines the effect of peanut protein skin contamination and skin appendage trapping. WP3 studies the immune system activation induced by massage and cutaneous peanut exposure. WP4 uses an intervention study approach with skin massage to study the immune responses to peanut allergen in those with a skin barrier defect. WP5 examines the cutaneous immune responses to peanut allergen in those suffering of peanut allergy, and, WP6 translates our findings through working with an industrial peanut processing partner, patients and consumers. Impact of expected results: We will work with the food industry, Allergy UK, the Natasha Allergy Research Foundation, as well as national and international food standards agencies to ensure stakeholder awareness and that the findings of our work are translated into improved public health measures. |
Impact | Not yet |
Start Year | 2021 |
Description | Preventing peanut allergy through improved understanding of the transcutaneous sensitisation route, novel food processing and skin care adaptations (TRANS-FOODS) |
Organisation | University of Bonn |
Country | Germany |
Sector | Academic/University |
PI Contribution | As part of this consortium, I provide expertise on food allergy and risk factors for sensitisation and allergic reactions and also about peanut allergens, their allergenicity and effect of their modification. In my laboratory at King's College London, my team will test the samples of interstitial fluid retrieved from the skin of adults participating in the clinical study planned as part of WP4 to assess the ability of peanut proteins contained in the interstitial skin fluid to interact with immune cells. Specifically, I plan is to use these samples to stimulate basophils in whole blood collected from peanut allergic donors, alongside the relevant controls, and assess basophil activation by flow cytometry. The basophil activation assay to peanut is well established in my laboratory. I have previously shown that it has 97% accuracy with 98% sensitivity and 96% specificity to diagnose peanut allergy with basophil activation being detectable below 1ng/ml of peanut protein. The basophil activation test is therefore a very sensitive and specific method to detect the presence and the allergenicity of peanut proteins. The basophil activation test can be very informative to demonstrate retained allergenicity and immunogenicity of peanut proteins that have crossed the skin barrier in adults, with or without atopic eczema, who have applied different peanut-containing preparations on to the skin. The evidence that sensitisation to food allergens can occur through the skin and the demonstration of the mechanisms by which this happens can potentially identify ways to reduce allergen exposure and to prevent the development of peanut and other food allergies in infants and children and possibly later in the life course. |
Collaborator Contribution | Background: Allergic diseases, including atopic dermatitis (AD) and food allergies (FA), affect over a quarter of all children across Europe. The immune responses to oral food allergens are well-established and controlled oral allergen exposure methods in early life have been developed that can prevent FA. However, it is not easy to comply with the repeated oral allergen exposure required to induce tolerance and additional approaches are therefore needed. There is mounting evidence that early life cutaneous exposure to foods causes sensitisation, especially in the presence of dry skin and AD. Despite this, very little is known about how the cutaneous sensitisation to FA occurs. Aims: This project aims to reduce the risk of peanut allergy development through the transcutaneous route by 1) understanding the mechanisms through which this occurs, and 2) designing and testing novel prevention approaches, such as modification in the peanut manufacturing processes and the adaptation of skin care practices. Workplan: These ambitious, but achievable aims are addressed in integrated workpackages, taken forward by leaders in their respective fields from the UK, Germany, and France: WP1 addresses the effects of food processing upon the solubility of peanut protein and its components in oil and how this relates to the cutaneous exposure to peanut protein. WP2 examines the effect of peanut protein skin contamination and skin appendage trapping. WP3 studies the immune system activation induced by massage and cutaneous peanut exposure. WP4 uses an intervention study approach with skin massage to study the immune responses to peanut allergen in those with a skin barrier defect. WP5 examines the cutaneous immune responses to peanut allergen in those suffering of peanut allergy, and, WP6 translates our findings through working with an industrial peanut processing partner, patients and consumers. Impact of expected results: We will work with the food industry, Allergy UK, the Natasha Allergy Research Foundation, as well as national and international food standards agencies to ensure stakeholder awareness and that the findings of our work are translated into improved public health measures. |
Impact | Not yet |
Start Year | 2021 |
Description | STOPPING ECZEMA AND ALLERGY (SEAL) STUDY: PREVENT THE ALLERGIC MARCH BY ENHANCING THE SKIN BARRIER |
Organisation | Benaroya Research Institute |
Country | United States |
Sector | Academic/University |
PI Contribution | I have contributed to this collaboration with my expertise on basophil and mast cell responses to food allergens in high risk children and using in vitro assays. My team in my laboratory will be testing samples from children recruited into the Seal study on the mast cell activation test that I have established in my lab. |
Collaborator Contribution | Stanford, Chicago, Denver and London will be the clinical sites recruiting patients for the Seal Study. Immune mechanistic work will also be undertaken at the sites, namely: skin barrier (Denver), microbiome (Chicago), T cells (Stanford) and mast cells (London). |
Impact | Brough HA, Lanser BJ, Sindher SB, Teng JMC, Leung DYM, Venter C, Chan SM, Santos AF, Bahnson HT, Guttman-Yassky E, Gupta RS, Lack G, Ciaccio CE, Sampath V, Nadeau KC, Nagler CR. Early intervention and prevention of allergic diseases. Allergy 2021; doi: 10.1111/all.15006. |
Start Year | 2020 |
Description | STOPPING ECZEMA AND ALLERGY (SEAL) STUDY: PREVENT THE ALLERGIC MARCH BY ENHANCING THE SKIN BARRIER |
Organisation | National Jewish Medical and Research Center, USA |
Country | United States |
Sector | Academic/University |
PI Contribution | I have contributed to this collaboration with my expertise on basophil and mast cell responses to food allergens in high risk children and using in vitro assays. My team in my laboratory will be testing samples from children recruited into the Seal study on the mast cell activation test that I have established in my lab. |
Collaborator Contribution | Stanford, Chicago, Denver and London will be the clinical sites recruiting patients for the Seal Study. Immune mechanistic work will also be undertaken at the sites, namely: skin barrier (Denver), microbiome (Chicago), T cells (Stanford) and mast cells (London). |
Impact | Brough HA, Lanser BJ, Sindher SB, Teng JMC, Leung DYM, Venter C, Chan SM, Santos AF, Bahnson HT, Guttman-Yassky E, Gupta RS, Lack G, Ciaccio CE, Sampath V, Nadeau KC, Nagler CR. Early intervention and prevention of allergic diseases. Allergy 2021; doi: 10.1111/all.15006. |
Start Year | 2020 |
Description | STOPPING ECZEMA AND ALLERGY (SEAL) STUDY: PREVENT THE ALLERGIC MARCH BY ENHANCING THE SKIN BARRIER |
Organisation | Stanford University |
Country | United States |
Sector | Academic/University |
PI Contribution | I have contributed to this collaboration with my expertise on basophil and mast cell responses to food allergens in high risk children and using in vitro assays. My team in my laboratory will be testing samples from children recruited into the Seal study on the mast cell activation test that I have established in my lab. |
Collaborator Contribution | Stanford, Chicago, Denver and London will be the clinical sites recruiting patients for the Seal Study. Immune mechanistic work will also be undertaken at the sites, namely: skin barrier (Denver), microbiome (Chicago), T cells (Stanford) and mast cells (London). |
Impact | Brough HA, Lanser BJ, Sindher SB, Teng JMC, Leung DYM, Venter C, Chan SM, Santos AF, Bahnson HT, Guttman-Yassky E, Gupta RS, Lack G, Ciaccio CE, Sampath V, Nadeau KC, Nagler CR. Early intervention and prevention of allergic diseases. Allergy 2021; doi: 10.1111/all.15006. |
Start Year | 2020 |
Description | STOPPING ECZEMA AND ALLERGY (SEAL) STUDY: PREVENT THE ALLERGIC MARCH BY ENHANCING THE SKIN BARRIER |
Organisation | University of Chicago |
Country | United States |
Sector | Academic/University |
PI Contribution | I have contributed to this collaboration with my expertise on basophil and mast cell responses to food allergens in high risk children and using in vitro assays. My team in my laboratory will be testing samples from children recruited into the Seal study on the mast cell activation test that I have established in my lab. |
Collaborator Contribution | Stanford, Chicago, Denver and London will be the clinical sites recruiting patients for the Seal Study. Immune mechanistic work will also be undertaken at the sites, namely: skin barrier (Denver), microbiome (Chicago), T cells (Stanford) and mast cells (London). |
Impact | Brough HA, Lanser BJ, Sindher SB, Teng JMC, Leung DYM, Venter C, Chan SM, Santos AF, Bahnson HT, Guttman-Yassky E, Gupta RS, Lack G, Ciaccio CE, Sampath V, Nadeau KC, Nagler CR. Early intervention and prevention of allergic diseases. Allergy 2021; doi: 10.1111/all.15006. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | Addenbrooke's Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | King's College Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | King's College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | Royal Manchester Children's Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | Sandwell and West Birmingham Hospitals NHS Trust |
Department | Rheumatology Sandwell and West Birmingham |
Country | United Kingdom |
Sector | Public |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | Sheffield Children's Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | Southampton Hospital |
Country | United States |
Sector | Hospitals |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | University College Hospital |
Country | United Kingdom |
Sector | Hospitals |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | University Hospitals of Leicester NHS Trust |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | UK Multicentre biomarker-led randomised-controlled trial of the basophil and mast cell activation tests in food allergy |
Organisation | University of Edinburgh |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have designed the study and will be distributing electronic clinical questionnaires as well as centralising the blood samples to perform the basophil and mast cell activation studies to the various allergens. |
Collaborator Contribution | The various partners will be consenting participants and send their anonymised clinical information as well as blood samples to KCL. |
Impact | No outputs yet. |
Start Year | 2020 |
Description | BBC World Service Programme The Evidence: Are allergies on the rise globally? |
Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | Claudia Hammond and guests discussed allergies and examined whether allergies are still on the increase and what can be done to prevent them. Claudia presented the event and interviewed the speakers. Then the audience had the opportunity to ask questions. The event was recorded live with an audience and edited into a programme to be broadcast on the BBC World Service as part of 'The Evidence' series. After broadcast, episodes of 'The Evidence' became available on the BBC website. Speakers: • Claudia Hammond (chair) • Professor Alexandra Santos, King's College London • Professor Carsten Flohr, King's College London • Professor Sejal Saglani, Imperial College London • Dr Paul Turner, Imperial College London Location: Wellcome Collection, 183 Euston Rd, London, NW1 2BE Level 2, Reading Room |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.bbc.co.uk/sounds/play/w3ct5l4j |
Description | Celebration of the International Day of Immunology (World Immunology Day) 2023 at the Francis Crick Institute: "Allergy: A misguided immune response in our lungs, skin or gut" |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Public/other audiences |
Results and Impact | In 2023, the Crick marked the International Day of Immunology 2023 with an expert public panel discussion about allergies chaired by award-winning BBC broadcaster Claudia Hammond. A panel of experts were invited to explain how allergies occur when the immune system mistakes harmless, everyday substances for potentially dangerous ones. This was a hybrid event, with an in-person audience at the Crick joined by online attendees. There were opportunities for questions from the in person and online audiences. This scientific panel discussion was aimed at the interested public and students from year 13 and beyond. This event was held in partnership with the Francis Crick Institute, Nature Portfolio, and the British Society for Immunology. • Chaired by award-winning BBC Broadcaster Claudia Hammond The panel: • Professor Carsten Flohr | Head, Paediatric & Population-Based Dermatology Research St Johns Institute of Dermatology, King's College London • Professor Clare Lloyd | Head, NHLI, Imperial College London • Professor Alexandra Santos | Clinical Professor of Paediatric Food Allergy, King's College London • Dr Paul Turner | Reader in Paediatric Allergy & Clinical Immunology; Faculty of Medicine, National Heart & Lung Institute, Imperial College London Eventbrite link: https://www.crick.ac.uk/whats-on/world-immunology-day-allergy-a-misguided-immune-response-in-our-lungs-skin-or-gut |
Year(s) Of Engagement Activity | 2023 |
URL | https://www.crick.ac.uk/whats-on/world-immunology-day-allergy-a-misguided-immune-response-in-our-lun... |
Description | FARE Online Research Retreat 2023 |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Online event organised by the largest patient group in the USA with an international reach. The purpose was to update patients and the general public about recent developments in food allergy research. My talk was entitled "Basophil and mast cell activation as biomarkers of food allergy and oral tolerance". |
Year(s) Of Engagement Activity | 2015,2022 |
URL | https://www.foodallergy.org/take-action/contains-courage-research-retreat |
Description | FARE Research Retreat for patients and public |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | • FARE Research Retreat for patients - lecture and Q&A about "Ex-vivo cellular activation assays in the diagnosis and monitoring of food allergy - online event, 21/09/2020 |
Year(s) Of Engagement Activity | 2020 |
Description | FDA Workshop on Biomarkers in Food Allergy and Asthma |
Form Of Engagement Activity | A talk or presentation |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Policymakers/politicians |
Results and Impact | "FDA Workshop: Biomarkers in the Development of Therapeutics for Allergic Diseases," held at the FDA on Thursday, February 22, 2024. The goals of the workshop were: 1. To inform stakeholders about FDA's biomarker program and requirements for biomarkers to be accepted for use in clinical trials. 2. To inform FDA regulators of the current status and future potential of diagnostic, prognostic, and predictive biomarkers in allergic respiratory disease (e.g., asthma endotypes) and food allergy. 4. To inform FDA regulators of the status of potential predictive biomarkers that may arise before the measured clinical response to AIT-T cell subsets, ILC subsets, blocking antibodies. 5. To inform FDA regulators of the status of monitoring/response biomarkers that may act as surrogates for our current clinical endpoints. This includes BAT and possibly the T cell, ILC markers above, possibly non-cellular markers as well. The hybrid public workshop was held between 8AM-5PM in the Great Room in Building 31 on the FDA campus in Silver Spring, MD. The workshop was divided into three sessions. The first session was comprised of speakers from the FDA to inform the community about the FDA Biomarkers program. The second and third sessions were comprised of speakers who will speak about biomarkers in respiratory allergic disease and food allergy, respectively. The talks were followed by active discussion. |
Year(s) Of Engagement Activity | 2024 |
URL | https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/biomarker-driven-drug-develop... |
Description | Virtual Food Allergy Fund Summit 2020 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Patients, carers and/or patient groups |
Results and Impact | Online Lecture "New approaches to the diagnosis of peanut allergy" at the Virtual Food Allergy Fund Summit 2020, 14th May 2020 |
Year(s) Of Engagement Activity | 2020 |